ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0106

A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0142

A Systemic Autoinflammatory Syndrome Caused by NEMO Exon 5 Skipping

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0225

A Transitions Retreat: Preparing Rheumatology Fellows for Career Planning and the Scholarly Phase of Training

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0218

A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0397

Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0057

Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

1:00PM-3:00PM: Abstract Number: 0195

Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0167

Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0410

Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0114

Addressing Healthcare Disparities Through Implementation of a Medical Student-Based Patient Navigator Program

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0033

Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0454

Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0128

Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0448

All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0467

All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].